Catastrophism in Chronic Inflammatory Rheumatism (CRIC)

Centre Hospitalier Universitaire de Nīmes

Status: Completed

Conditions: Chronic Inflammatory Rheumatism

Treatments: Other: completing self-questionnaires

Study type: Interventional

Funder types: Other

Identifiers

NCT04174092

2019.A01715-52 (Other Identifier)

LOCAL 2019/CGV/01

Details and patient eligibility

About

Catastrophic is defined as a negative cognitive and emotional response based on inadequate pain expression. It has three components: rumination, amplification and vulnerability. The assessment of catastrophism is carried out using a validated questionnaire called the "Pain Catatrophizing Scale" (PCS).

Recent studies highlight the significant impact of catastrophism in neuromuscular and mechanical rheumatic diseases such as gonarthrosis gonalgia and low back pain. In these diseases, it has been shown that catastrophism has a negative impact both on the experience of pain and on the response to different types of treatments (medical and surgical). Several studies have implemented multidisciplinary management and in particular cognitive-behavioural therapy with an improvement in the pain experience in patients who are catastrophic.

In chronic inflammatory rheumatic diseases such as rheumatoid arthritis, spondyloarthritis and psoriatic arthritis, the prevalence and impact of catastrophism is still poorly understood.

Enrollment: 533 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Major patients, hospital follow-up, with RA according to ACR 2010 criteria, or spondyloarthritis according to ASAS 2009 criteria or according to AMOR or psoriatic arthritis according to Caspar 2006 criteria.
• Patient who has given free and informed consent.
• Patient who has signed the consent form.
• Patient affiliated or benefiting from a health insurance plan.
• Adult patient (≥18 years old).

Exclusion criteria

• Patient under the protection of justice, under guardianship or curatorship.
• Patient unable to express consent.
• Patient for whom it is impossible to provide informed information.
• Poor command and understanding of the French language making it impossible to complete self-questionnaires

Trial design

Primary purpose: Diagnostic

Allocation: Non-Randomized

Interventional model: Parallel Assignment

Masking: None (Open label)

---

533 participants in 3 patient groups

rheumatoid arthritis

Experimental group

Description:

Filling in several self-questionnaires: on function (HAQ), pain EVA, quality of life (SF12, EQ5D), anxiety score (GAD-7), insomnia score (ISI), catastrophic score (PCS), coping score (coping ability, CSQ), compliance scores (CQR, Health Insurance Compliance Assessment Questionnaire) and fibromyalgia diagnostic score (FiRST), activity of rheumatic disease (RAID, RAPID-3) Patients will be seen at 3, 6 and 12 months

Treatment:

Other: completing self-questionnaires

spondyloarthritis

Experimental group

Description:

Filling in several self-questionnaires: on function (HAQ), pain EVA, quality of life (SF12, EQ5D), anxiety score (GAD-7), insomnia score (ISI), catastrophic score (PCS), coping score (coping ability, CSQ), compliance scores (CQR, Health Insurance Compliance Assessment Questionnaire) and fibromyalgia diagnostic score (FiRST), activity of rheumatic disease (BASDAI, BASFI). Patients will be seen at 3, 6 and 12 months

Treatment:

Other: completing self-questionnaires

Psoriatic arthritis

Experimental group

Description:

Filling in several self-questionnaires: on function (HAQ), pain EVA, quality of life (SF12, EQ5D), anxiety score (GAD-7), insomnia score (ISI), catastrophic score (PCS), coping score (coping ability, CSQ), compliance scores (CQR, Health Insurance Compliance Assessment Questionnaire) and fibromyalgia diagnostic score (FiRST), activity of rheumatic disease (BASDAI, BASFI). Patients will be seen at 3, 6 and 12 months

Treatment:

Other: completing self-questionnaires